1H-四唑-5-戊腈 | 1064596-41-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1H-四唑-5-戊腈
• 英文名称: 5-(1H-tetrazol-5-yl)pentanenitrile
• 英文别名: 1H-tetrazole-5-pentanenitrile；5-(2H-tetrazol-5-yl)pentanenitrile
• CAS: 1064596-41-3
• 化学式: C₆H₉N₅
• 分子量: 151.171
• InChiKey: UZXZYQFBJSCJQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  78.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1H-四唑-5-戊腈 在 三氟化硼乙醚 、 4-甲基苯磺酸吡啶 、 三乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 49.0h， 生成 α-[(3aR,4R,5R,6aS)-4-[(1E,3S)-3-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-4-methyl-1-octenyl]hexahydro-5-hydroxy-2H-cyclopenta[b]furan-2-ylidene]-1H-tetrazole-5-2E-pentanenitrile
  参考文献：
  名称：

  WO2008/116670

  摘要：

  公开号：
• 作为产物：
  描述：

  己二腈 在 sodium azide 、 氯化铵 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 1H-四唑-5-戊腈
  参考文献：
  名称：

  Novel 5-cyano-prostacyclin derivatives as agents for the treatment of influenza a viral infection

  摘要：

  该发明涉及式(I)的化合物： 其中A、B、D、E、m和R1-R5如本文所述，可以是单一立体异构体或立体异构体混合物，或其药学上可接受的盐、包合物或前药。这些化合物可用于治疗与流感A病毒相关的呼吸道疾病，例如H5N1及其突变体。本发明还涉及包含所述化合物的药物组合物以及制备所述化合物的方法。

  公开号：

  US20080242714A1

文献信息

• Novel 5-cyano-prostacyclin derivatives and their use as agents for the treatment of influenza a viral infection
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1975163A1

  公开（公告）日：2008-10-01

  This invention is directed to compounds of formula (I): where A, B, D, E, m, and R1 - R5 are as described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, clathrates, or prodrugs thereof, which compounds are useful in treating respiratory diseases associated with influenza A viruses, such as for example H5N1 and its mutations. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

  本发明涉及以下式(I)的化合物：其中A、B、D、E、m和R1 - R5如本文所述，可以是单个立体异构体或立体异构体混合物，或其药学上可接受的盐、包合物或前药，这些化合物在治疗与流感A病毒相关的呼吸道疾病方面有用，例如H5N1及其突变体。还公开了包含本发明化合物的药物组合物和制备本发明化合物的方法。
• Novel 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases
  申请人：Guilford William

  公开号：US20080242713A1

  公开（公告）日：2008-10-02

  This invention is directed to compounds of formula (I): where A, B, D, E, m, and R 1 -R 5 are as described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, clathrates, or prodrugs thereof, which compounds are useful in treating autoimmune diseases. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

  本发明涉及具有以下结构的化合物（I）：其中A、B、D、E、m和R1-R5如本文所述，可以是单一立体异构体或立体异构体混合物，或其药学上可接受的盐、包合物或前药，这些化合物可用于治疗自身免疫疾病。本发明还涉及包含所述化合物的药物组合物以及制备所述化合物的方法。
• 5-cyano-prostacyclin derivatives as agents for the treatment of influenza a viral infection
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：US07776896B2

  公开（公告）日：2010-08-17

  This invention is directed to compounds of formula (I): where A, B, D, E, m, and R1-R5 are as described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, clathrates, or prodrugs thereof, which compounds are useful in treating respiratory diseases associated with influenza A viruses, such as for example H5N1 and its mutations. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

  本发明涉及式(I)的化合物：其中A、B、D、E、m和R1-R5如本文所述，可以作为单一立体异构体或立体异构体混合物，或其药学上可接受的盐、包合物或前药，这些化合物在治疗与流感A病毒相关的呼吸系统疾病方面有用，例如H5N1及其突变体。本发明还公开了包含该化合物的制药组合物和制备该化合物的方法。
• Synthesis of 5-Substituted Tetrazoles: Reaction of Azide Salts with Organonitriles Catalyzed by Trialkylammonium Salts in Non-polar Media
  作者：Sarath C. Sarngadharan、Josh Aronson、Carol Gelbaum、Kris Griffith、Jonathan Faris、Azhar B. Moihdeen、Mikhil Patel、Maryellen Malone、Kent Richman、Charles A. Eckert、Charles L. Liotta、Pamela Pollet

  DOI：10.1021/acs.oprd.2c00032

  日期：2022.5.20

  An efficient synthesis of 5-substituted tetrazole derivatives via the addition of azide ions to an organonitrile is presented. This new protocol minimizes the potential generation of hydrazoic acid by employing a catalytic amount of an activating proton source (trialkylammonium chloride) in combination with a phase transfer agent (tetraalkylammonium salt). Both aromatic and aliphatic nitriles are successfully

  提出了一种通过将叠氮离子添加到有机腈中来有效合成 5-取代四唑衍生物的方法。这个新协议通过使用催化量的活化质子源（三烷基氯化铵）与相转移剂（四烷基铵盐）结合，最大限度地减少了潜在的叠氮酸产生。芳香族和脂肪族腈都成功地反应生成相应的 5-取代-1 H-四唑产物。还介绍了氯化胆碱作为相转移剂的优越性，催化质子源和相转移剂的可回收性，以及每种反应组分的拟议机制作用。
• Novel 5-cyano-prostacyclin derivatives and their use as agents for the treatment of autoimmune diseases
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1988087A1

  公开（公告）日：2008-11-05

  This invention is directed to compounds of formula (I): where A, B, D, E, m, and R1 - R5 are as described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, clathrates, or prodrugs thereof, which compounds are useful in treating autoimmune diseases. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

  本发明涉及式 (I) 化合物： 其中 A、B、D、E、m 和 R1 - R5 如本文所述，为单一立体异构体或立体异构体混合物，或其药学上可接受的盐、凝胶体或原药，这些化合物可用于治疗自身免疫性疾病。还公开了包含本发明化合物的药物组合物和制备本发明化合物的方法。